These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 26382906

  • 1. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M, Papp K.
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [Abstract] [Full Text] [Related]

  • 2. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S, Kavanaugh A.
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P.
    Biochem Pharmacol; 2012 Jun 15; 83(12):1583-90. PubMed ID: 22257911
    [Abstract] [Full Text] [Related]

  • 7. Apremilast for the treatment of psoriatic arthritis.
    Souto A, Gómez-Reino JJ.
    Expert Rev Clin Immunol; 2015 Jun 15; 11(12):1281-90. PubMed ID: 26503917
    [Abstract] [Full Text] [Related]

  • 8. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC, McNamee KE, McCann FE.
    Drug Des Devel Ther; 2013 Jun 15; 7():201-10. PubMed ID: 23569359
    [Abstract] [Full Text] [Related]

  • 9. Apremilast in psoriatic arthritis.
    Schett G.
    Clin Exp Rheumatol; 2015 Jun 15; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.
    J Rheumatol; 2015 Mar 15; 42(3):479-88. PubMed ID: 25593233
    [Abstract] [Full Text] [Related]

  • 12. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep 15; 53(9):105-8. PubMed ID: 26358317
    [Abstract] [Full Text] [Related]

  • 13. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED.
    Drugs; 2015 Aug 15; 75(12):1393-403. PubMed ID: 26220911
    [Abstract] [Full Text] [Related]

  • 14. [Gastrointestinal side effects of apremilast : Characterization and management].
    Pinter A, Beigel F, Körber A, Homey B, Beissert S, Gerdes S, Staubach-Renz P, Radtke MA, Mössner R.
    Hautarzt; 2019 May 15; 70(5):354-362. PubMed ID: 30937481
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG.
    J Drugs Dermatol; 2018 Aug 01; 17(8):835-840. PubMed ID: 30124722
    [Abstract] [Full Text] [Related]

  • 16. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T, Puig L.
    Am J Clin Dermatol; 2018 Feb 01; 19(1):23-32. PubMed ID: 28597182
    [Abstract] [Full Text] [Related]

  • 17. Apremilast for the treatment of psoriatic arthritis.
    Varada S, Tintle SJ, Gottlieb AB.
    Expert Rev Clin Pharmacol; 2014 May 01; 7(3):239-50. PubMed ID: 24702658
    [Abstract] [Full Text] [Related]

  • 18. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M.
    J Dermatol; 2018 Nov 01; 45(11):1345-1348. PubMed ID: 30168880
    [Abstract] [Full Text] [Related]

  • 19. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R, Alikhan A.
    Expert Rev Clin Pharmacol; 2017 Apr 01; 10(4):349-360. PubMed ID: 28276777
    [Abstract] [Full Text] [Related]

  • 20. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A.
    J Rheumatol; 2016 Sep 01; 43(9):1724-34. PubMed ID: 27422893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.